Good Pharmacovigilance Practice (GVP) Audit & Compliance Consulting

Targeted Consulting and Audit Solutions to Strengthen Global Pharmacovigilance Systems

Man holding drugs reviewing the labels

What are GVPs?

Good Pharmacovigilance Practices (GVP) are the standards and guidelines that describe how pharmacovigilance should be performed to make sure medicines are monitored safely and consistently, covering:

  • Collecting and managing adverse event (AE) reports
  • Signal detection and risk assessment
  • Writing safety reports (PSUR/PBRER, RMPs, etc.)
  • Inspections and quality systems
  • Ensuring compliance across the product lifecycle

ProPharma provides specialized Good Vigilance Practices (GVP) readiness, compliance consulting, and pharmacovigilance (PV) audit services to support life sciences organizations operating globally in the United States, the European Union, and the APAC region. Our experts partner with clients to evaluate, design, and strengthen pharmacovigilance systems to meet regulatory expectations, ensure inspection readiness, and maintain continuous patient safety oversight.

Jogging or running icon

PV Readiness Evaluations

PV Readiness Evaluations

Document search icon

CAPA and Remediation

CAPA and Remediation

Medical writing icon

Inspection Readiness Training

Inspection Readiness Training

global-connections-icon-purple

Mock Regulatory Inspection

Mock Regulatory Inspection

Service icon

Continued Support

Continued Support

PV Readiness Evaluations

  • End-to-end PV System Gap Assessment – Benchmark against FDA 21 CFR, EU GVP Modules, ICH E2, and local HA requirements
  • PSMF / PV Master File Review & Reconstruction – Structure, accuracy, annex completeness, and inspection defensibility
  • Vendor & Partner Oversight Evaluation – SDEAs, metrics, audits, escalation pathways
  • Case Processing & Reporting Compliance Review – Timeliness, data quality, MedDRA coding, narrative robustness
  • Signal Management & Risk Management Assessment – Signal detection methodology, documentation, governance
  • QMS Integration Review – SOP hierarchy, change control, training traceability
  • Data Integrity & Inspection Traceability Testing – Audit trails, reconciliation, source-to-submission checks
  • Inspection Risk Heat Map & Readiness Scorecard – Prioritized risks with regulatory exposure rating
Person using a laptop with internet icons floating

CAPA and Remediation

  • Root Cause Analysis (RCA) – Use of structured methodologies (5-Why, Fishbone, Fault Tree)
  • Regulatory-Grade CAPA Plan Development – Clear linkage between finding → root cause → corrective/preventive action
  • Inspection Response Authoring Support – FDA 483, EMA List of Questions, PMDA findings
  • CAPA Effectiveness Checks (ECs) – Metrics, trend analysis, sustainability validation
  • Process Redesign & SOP Remediation – Alignment with HA expectations and inspection language
  • System Remediation Oversight – Safety databases, tracking tools, reconciliation processes
  • Management Escalation & Governance Support – Oversight committees, quality review boards
  • Regulatory Follow-Up Readiness – Re-inspection and verification preparedness
Man holding drugs reviewing the labels

Inspection Readiness Training

  • Role-Based Inspection Training – Executives, PV/QMS staff, SMEs, QA, IT, vendors
  • Inspector Interaction & Interview Skills Training – Answer framing, document control, demeanor
  • PV-Specific Inspection Modules – Case walkthroughs, signal defense, safety governance
  • Data Integrity & Documentation Best Practices – ALCOA+, contemporaneous documentation
  • Front Room / Back Room Simulation Training – Inspection command center models
  • Global HA Expectations Training – FDA vs EMA vs MHRA vs PMDA nuances
  • Do's and Don'ts Playbooks – Verbal responses, document provision, escalation rules
Two women in lab coats reviewing a laptop in a laboratory

Mock Regulatory Inspection

  • Inspection Scope & Agenda Design – Aligned to product type, region, and risk profile
  • Opening & Closing Meeting Simulation – Senior leadership participation
  • Live System & Process Walkthroughs – Safety database, QMS, signal management, RMPs
  • Interviews of Key Personnel – PV QPPV, safety physicians, QA, IT, vendors
  • Document Request & Tracking Drills – Timeliness, version control, inspection logs
  • Real-Time Observation & Deficiency Identification – Inspection-style findings and evidence citation
  • Mock 483 / Findings Issuance – Written in HA tone and structure
  • Readiness Debrief & Executive Readout – Critical vs major vs minor risks
Medical Information - 3-1

Continued Support

  • Inspection Ready Room Support – Real-time response coordination during inspection
  • On-Demand SME Support – PV, QA, regulatory, IT, data integrity
  • Health Authority Correspondence Management – LOIs, follow-up questions, commitments tracking
  • Sustained Readiness Program Management – Periodic health checks and readiness refreshes
  • Continuous Improvement & Trend Monitoring – Metrics, recurring issues, emerging regulatory focus
  • Vendor & Partner Readiness Oversight – Joint inspections, audits, remediation alignment
  • Re-inspection & Surveillance Audit Preparation – Long-term compliance sustainability
Finger pointing at pie chart on a desk.

Contact Our GVP Team

Partner with us for expert PV compliance and auditing solutions. Contact ProPharma today to learn how we can support your organization’s PV governance and Quality Assurance needs.

GVP Readiness & Compliance Consulting

In addition to providing ProPharma supports organizations at all stages of pharmacovigilance maturity, from early system development to ongoing compliance optimization. Our GVP readiness and compliance consulting services are designed to identify gaps, mitigate regulatory risk, and establish sustainable PV quality systems aligned with global requirements.

Gap Assessments Against Global PV Requirements

Our compliance consultants conduct structured gap assessments to evaluate pharmacovigilance systems against applicable regulatory frameworks, including:

  • FDA post-marketing safety reporting requirements (21 CFR, FDA guidance)
  • EMA Good Pharmacovigilance Practices (GVP) Modules I–XVI
  • Regional and country-specific PV requirements across EU Member States and APAC markets

Assessments focus on governance, processes, documentation, and oversight to identify compliance gaps, operational risks, and areas requiring remediationremediation needs.

PV System Development & Optimization

ProPharma assists firms in designing, implementing, and enhancing scalable, inspection-ready, and globally aligned pharmacovigilance systems. Support includes:

Our approach ensures systems are practical, sustainable, and aligned with both regulatory expectations and business needs.

Quality System Master File (QSMF/PSMF) Support

ProPharma provides expert support for the development, remediation, and maintenance of Quality System Master Files / Pharmacovigilance System Master Files (PSMF), including:

We ensure documentation accurately reflects operational practice and regulatory expectations.

PV Audits & GVP Compliance Assessments

Independent, Risk-Based Audits to Ensure PV System Effectiveness and Compliance

ProPharma delivers comprehensive pharmacovigilance audit services to evaluate compliance, effectiveness, and regulatory readiness across global PV operations. Our audits are conducted by experienced PV auditors with deep regulatory and operational expertise.

Floating holographic documents
health-care-worker-with-latex-gloves-typing-on-keyboard-ss-1322036018-650x425

Structured GVP and PV System Audits

Our audit programs are tailored to client needs and regulatory risk profiles, with a scope that may include:

  • Overall pharmacovigilance system governance and oversight
  • SOPs, policies, and controlled documentation
  • Adverse event case intake, processing, and reporting
  • Literature surveillance and safety data review
  • Signal detection, evaluation, and documentation
  • Aggregate reporting processes (PSUR/PBRER, safety summaries)

Audits are aligned with EMA GVP Modules, FDA expectations, and other applicable regional requirements.

Internal, Affiliate, and Third-Party PV Audits

ProPharma conducts a full range of PV audits, including:

  • Internal PV audits of sponsor pharmacovigilance functions
  • Affiliate audits to assess local PV implementation and oversight
  • Supplier and vendor audits, including CROs, call centers, and safety service providers
  • License Partner and PV Sponsor audits to evaluate contractual compliance, safety data exchange, and oversight responsibilities
  • Our audits support both initial qualification and ongoing oversight programs.

Actionable Findings & Remediation Support

Audit deliverables include clear, risk-based findings, practical recommendations, and prioritized remediation actions. ProPharma can also support:

Our Consulting & Audit Approach

ProPharma applies a consistent, inspection-focused methodology designed to deliver compliance, and confidence. Our audit approach emphasizes:

  • Regulatory alignment across the US, EU, and APAC regions
  • Practical, risk-based recommendations
  • Collaboration with client teams to drive sustainable improvements
  • Clear documentation suitable for regulatory inspection and audit defense
Scientist in Sterile Coverall Walking with Laptop Computer, Examining Industrial CNC Machine Settings and Configuring Production

Frequently Asked Questions

What is the difference between GVP readiness consulting and a PV audit?

GVP readiness consulting focuses on proactive assessment, system design, and remediation support, while PV audits provide...

Read More

What is the difference between GVP readiness consulting and a PV audit?

GVP readiness consulting focuses on proactive assessment, system design, and remediation support, while PV audits provide independent evaluation of compliance and effectiveness against regulatory standards.

Read Less

When should a company conduct a PV gap assessment?

PV gap assessments are recommended prior to first marketing authorization, following organizational changes, before regulatory inspections, or when...

Read More

When should a company conduct a PV gap assessment?

PV gap assessments are recommended prior to first marketing authorization, following organizational changes, before regulatory inspections, or when expanding into new regions or partnerships.

Read Less

Do you audit vendors and license partners outside the EU?

Yes. ProPharma conducts global PV audits, including vendors, affiliates, and license partners across the US, EU, APAC, and other regions.

Do you audit vendors and license partners outside the EU?

Yes. ProPharma conducts global PV audits, including vendors, affiliates, and license partners across the US, EU, APAC, and other regions.

Read Less

Can ProPharma support CAPA remediation after an audit?

Absolutely. We provide hands-on support for CAPA development, implementation, and follow-up assessments to ensure effective and sustainable...

Read More

Can ProPharma support CAPA remediation after an audit?

Absolutely. We provide hands-on support for CAPA development, implementation, and follow-up assessments to ensure effective and sustainable remediation.

Read Less

Are audits aligned with both FDA, EMA, MHRA, and ROW health authority expectations?

Yes. Our audits are designed to align with global GVP Modules, pharmacovigilance requirements, and applicable...

Read More

Are audits aligned with both FDA, EMA, MHRA, and ROW health authority expectations?

Yes. Our audits are designed to align with global GVP Modules, pharmacovigilance requirements, and applicable regional regulations.

Read Less

Contact Our GVP Team

Partner with us for expert PV compliance and auditing solutions. Contact ProPharma today to learn how we can support your organization’s PV governance and Quality Assurance needs.

Good Pharmacovigilance Practices Articles

Understanding the PSUR and PBRER

Understanding the PSUR and PBRER

Periodic Safety Update Reports (PSURs) play a pivotal role in ensuring the ongoing safety and efficacy of medicinal products once they've entered the market. While initial clinical trials provide...

An Overview of the PSMF: Pharmacovigilance System Master File

An Overview of the PSMF: Pharmacovigilance System Master File

What is a PSMF? The EU Pharmacovigilance System Master File (PSMF) is a legally required document created and maintained by a Marketing Authorisation Holder (MAH). Essentially, the document is a...

How to Spring Clean Your PV Safety Data for Optimal Performance

How to Spring Clean Your PV Safety Data for Optimal Performance

As the blossoms of spring usher in a season of renewal, it's not just our homes that could use a thorough cleaning – our safety data deserves a refreshing sweep too. In an enlightening conversation...

News & Insights

From Defensible to Predictive: How High-Functioning MLR Teams Are Evolving Their Risk Assessment Approach

October 21, 2026

From Defensible to Predictive: How High-Functioning MLR Teams Are Evolving Their...

Recent FDA enforcement activity is changing how MLR teams assess promotional risk. Learn why organizations are moving from defensible claims to predictive, enforcement-informed risk assessment.

AI-Readiness 101: AI Success Starts with Understanding Your Data

October 19, 2026

AI-Readiness 101: AI Success Starts with Understanding Your Data

Unlock AI success by understanding your data. Learn the foundations of AI readiness and how to build trust in your data for reliable insights.

What It Takes to Build a Successful Global Medical Information Program in Veterinary Medicine

October 13, 2026

What It Takes to Build a Successful Global Medical Information Program in Veteri...

Learn how to build a successful global medical information program in veterinary medicine, navigating complexity and enhancing customer support across diverse markets.

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Accelerating Clinical Trial Activation Across Latin America - ProPharma

October 20, 2026

Accelerating Clinical Trial Activation Across Latin America

Launching clinical trials across multiple countries requires navigating varying regulatory requirements, site contracts, translations, import/export processes, and site engagement activities, all...

Infographic Flexible Resourcing Without Limits: Scaling Capabilities Across the Development Lifecycle - ProPharma

September 18, 2026

Flexible Resourcing Without Limits: Scaling Capabilities Across the Development ...

Development complexity doesn’t increase in a straight line. As programs progress from discovery through Phase III, submission, and post-approval, demands for medical writing, biometrics, clinical...

Case Study Achieving Continuous Audit Readiness Across a Global Medical Information Program - ProPharma

August 3, 2026

Achieving Continuous Audit Readiness Across a Global Medical Information Program

Maintaining continuous audit readiness across a global Medical Information operation requires more than periodic audit preparation. Organizations operating across multiple countries and affiliates...

Beyond the Buzz: Leveraging Community Management to Enhance Medical Information

December 2, 2026

Beyond the Buzz: Leveraging Community Management to Enhance Medical Information

Patients, caregivers, and healthcare professionals are increasingly turning to digital channels to seek information, share experiences, and discuss treatments. Join this webinar to explore how...

Empowering Sites, Engaging Patients: Strategies to Improve Clinical Trial Performance 

November 12, 2026

Empowering Sites, Engaging Patients: Strategies to Improve Clinical Trial Performance 

Sites are being asked to do more than ever before while balancing increasing trial complexity, patient expectations, and operational demands. Join this webinar to explore how flexible, integrated...

Reg Reels: Your Snapshot of the Latest Pharmacovigilance Regulatory Developments

October 22, 2026

Reg Reels: Your Snapshot of the Latest Pharmacovigilance Regulatory Developments

Tired of working through lengthy regulatory documents? Join Reg Reels for a concise, video-led look at the latest pharmacovigilance developments from the EMA, FDA, and MHRA. Our experts will...

News & Insights

From Defensible to Predictive: How High-Functioning MLR Teams Are Evolving Their Risk Assessment Approach

October 21, 2026

From Defensible to Predictive: How High-Functioning MLR Teams Are Evolving Their...

Recent FDA enforcement activity is changing how MLR teams assess promotional risk. Learn why organizations are moving from defensible claims to predictive, enforcement-informed risk assessment.

AI-Readiness 101: AI Success Starts with Understanding Your Data

October 19, 2026

AI-Readiness 101: AI Success Starts with Understanding Your Data

Unlock AI success by understanding your data. Learn the foundations of AI readiness and how to build trust in your data for reliable insights.

What It Takes to Build a Successful Global Medical Information Program in Veterinary Medicine

October 13, 2026

What It Takes to Build a Successful Global Medical Information Program in Veteri...

Learn how to build a successful global medical information program in veterinary medicine, navigating complexity and enhancing customer support across diverse markets.

Previous Post Arrow Next Post Arrow
ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Accelerating Clinical Trial Activation Across Latin America - ProPharma

October 20, 2026

Accelerating Clinical Trial Activation Across Latin America

Launching clinical trials across multiple countries requires navigating varying regulatory requirements, site contracts, translations, import/export processes, and site engagement activities, all...

Infographic Flexible Resourcing Without Limits: Scaling Capabilities Across the Development Lifecycle - ProPharma

September 18, 2026

Flexible Resourcing Without Limits: Scaling Capabilities Across the Development ...

Development complexity doesn’t increase in a straight line. As programs progress from discovery through Phase III, submission, and post-approval, demands for medical writing, biometrics, clinical...

Case Study Achieving Continuous Audit Readiness Across a Global Medical Information Program - ProPharma

August 3, 2026

Achieving Continuous Audit Readiness Across a Global Medical Information Program

Maintaining continuous audit readiness across a global Medical Information operation requires more than periodic audit preparation. Organizations operating across multiple countries and affiliates...

Previous Resource Arrow Next Resource Arrow
Beyond the Buzz: Leveraging Community Management to Enhance Medical Information

December 2, 2026

Beyond the Buzz: Leveraging Community Management to Enhance Medical Information

Patients, caregivers, and healthcare professionals are increasingly turning to digital channels to seek information, share experiences, and discuss treatments. Join this webinar to explore how...

Empowering Sites, Engaging Patients: Strategies to Improve Clinical Trial Performance 

November 12, 2026

Empowering Sites, Engaging Patients: Strategies to Improve Clinical Trial Performance 

Sites are being asked to do more than ever before while balancing increasing trial complexity, patient expectations, and operational demands. Join this webinar to explore how flexible, integrated...

Reg Reels: Your Snapshot of the Latest Pharmacovigilance Regulatory Developments

October 22, 2026

Reg Reels: Your Snapshot of the Latest Pharmacovigilance Regulatory Developments

Tired of working through lengthy regulatory documents? Join Reg Reels for a concise, video-led look at the latest pharmacovigilance developments from the EMA, FDA, and MHRA. Our experts will...

Previous Webinar Arrow Next Webinar Arrow